NCT01655888View on ClinicalTrials.gov

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

PHASE2UnknownINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2015

Conditions

Malignant Mesothelioma

Interventions

DRUG

Tremelimumab

Tremelimumab is administered as endovenous infusion

Trial Locations (1)

53100

RECRUITING

Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

MedImmune LLC

INDUSTRY

lead

Azienda Ospedaliera Universitaria Senese

OTHER